ValiRx PLC - London-based clinical stage biotechnology company - Lays out strategy to build on portfolio of drug candidates in the oncology and women's health space. "The company plans to apply both intellectual and financial resources to each project and enable acceleration through pre-clinical development," ValiRx said.
Current stock price: 8.12 pence
Year-to-date change: down 46%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.